Improvement of inoculant efficiency by strain improvement and formulation manipulations

1990 ◽  
pp. 617-624 ◽  
Author(s):  
Alan S. Paau ◽  
Mari Lynn Bennett ◽  
Cara J. Kurtenbach ◽  
Lori L. Graham
Keyword(s):  
1992 ◽  
Vol 93 (3) ◽  
pp. 221-226 ◽  
Author(s):  
Soon Bai Chun ◽  
Jong Eon Chin ◽  
Suk Bai ◽  
Gil-Hwan An

New antibiotics are needed, ( a ) to control diseases that are refractory to existing ones either because of intrinsic or acquired drug resistance of the pathogen or because inhibition of the disease is difficult, at present, without damaging the host (fungal and viral diseases, and tumours), ( b ) for the control of plant pathogens and of invertebrates such as helminths, insects, etc., and ( c ) for growth promotion in intensive farming. Numerous new antibiotics are still being obtained from wild microbes, especially actinomycetes. Chemical modification of existing compounds has also had notable success. Here we explore the uses, actual and potential, of genetics to generate new antibiotics and to satisfy the ever-present need to increase yield. Yield improvement has depended in the past on mutation and selection, combined with optimization of fermentation conditions. Progress would be greatly accelerated by screening random recombinants between divergent high-yielding strains. Strain improvement may also be possible by the introduction of extra copies of genes of which the products are rate-limiting, or of genes conferring beneficial growth characteristics. Although new antibiotics can be generated by mutation, either through disturbing known biosyntheses or by activating ‘silent’ genes, we see more promise in interspecific recombination between strains producing different secondary metabolites, generating producers of ‘hybrid’ antibiotics. As with proposals for yield improvement, there are two major strategies for obtaining interesting recombinants of this kind: random recombination between appropriate strains, or the deliberate movement of particular biosynthetic abilities between strains. The development of protoplast technology in actinomycetes, fungi and bacilli has been instrumental in bringing these idealized strategies to the horizon. Protoplasts of the same or different species can be induced to fuse by polyethylene glycol. At least in intraspecific fusion of streptomycetes, random and high frequency recombination follows. Protoplasts can also be used as recipients for isolated DNA, again in the presence of polyethylene glycol, so that the deliberate introduction of particular genes into production strains can be realistically envisaged. Various kinds of DNA cloning vectors are being developed to this end. Gene cloning techniques also offer rich possibilities for the analysis of the genetic control of antibiotic biosynthesis, knowledge of which is, at present, minimal. The information that should soon accrue can be expected to have profound effects on the application of genetics to industrial microbiology.


2015 ◽  
Vol 55 (4) ◽  
pp. 440-446 ◽  
Author(s):  
Vakhtang V. Dzhavakhiya ◽  
Tatiana M. Voinova ◽  
Elena V. Glagoleva ◽  
Dmitry V. Petukhov ◽  
Alexander I. Ovchinnikov ◽  
...  
Keyword(s):  

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Ayman I Ayache ◽  
Kenya Kusunose ◽  
Hussain A Ismaeel ◽  
Muhammad Tariq ◽  
Deborah H Kwon ◽  
...  

Introduction: Reversible constrictive pericarditis (CP) has been described with resolution of constriction after treatment with anti-inflammatory medications. In our study, we assessed the improvement of biventricular myocardial strain in CP patients treated medically compared to CP patients who underwent pericardiectomy. Methods and Results: We compared myocardial mechanics by 2-dimensional speckle tracking in 16 CP patients (age: 56±13; 75% males) who received anti-inflammatory medications to an age and sex matched CP group (age: 57±12; 75% males) who underwent pericardiectomy. At baseline, both treatment groups had depressed left ventricular (LV) anterolateral wall strain (LWS) and right ventricular (RV) free wall longitudinal systolic strain (FWS) but preserved LV septal wall systolic strain (SWS). In a median follow-up of 150 days the medically treated patients showed improvement of the depressed LVLWS/LVSWS (Pre: 0.61±0.17, Post: 0.89±0.21;P<0.001) and a trend in RVFWS/LVSWS (Pre:0.66±0.45, Post:0.89±0.38;P=0.12), that is similar to the improvement of the depressed LVLWS/LVSWS (Pre: 0.85±0.12, Post: 0.92±0.1;P<0.05) and trend in RVFWS/LVSWS (Pre: 0.77±0.32, Post: 0.86±0.18;P=0.09) of post pericardiectomy patients at a median follow-up of 74 days. Conclusions: Biventricular myocardial strain imaging is a robust technique for assessment of response to anti-inflammatory therapy in CP patients. Medical treatment of CP leads to systolic strain improvement that is more pronounced in the LV and RV free walls, hence having similar impact on the biventricular myocardial mechanics as pericardiectomy.


INDIAN DRUGS ◽  
2013 ◽  
Vol 50 (11) ◽  
pp. 25-28
Author(s):  
K Narayanan ◽  
◽  
N.D. Chopade ◽  
V.M Subrahmanyam ◽  
J. Venkata Rao

Microbial chitinases are commercially exploited for their biocontrol properties and generation of useful products from chitinous waste. Availability of highly active chitinolytic enzymes is a major problem. The present study was carried out to improve chitinase production by Aspergillus terreus using a chemical mutagen, ethidium bromide. The organism was cultivated on lactose- yeast extract medium. The production medium consisting of chitin- yeast extract medium was seeded at 10% level. The wild strains were exposed to ethidium bromide in the concentration range 1.5- 6.0 µg/mL. Generally, all the mutated strains showed an improved chitinase yield compared to the control. Highest yield was observed with the strain exposed to 6 µg/mL of ethidium bromide. The yield was 25.03 % higher compared to the wild strain. The mutated strain was slimy in nature. Protein content of the mutated strain decreased by 11%. Ethidium bromide at a concentration of 1.5 µg/mL was considered optional, at which the strain was stable with increase of 21.80 % in enzyme activity and 4.41% increase in protein content. Increased enzyme yield with decreased non-specific protein could be useful in producing cost effective enzyme.


Author(s):  
Herman Suryadi ◽  
Marina Ika Irianti ◽  
Tri Hastuti Septiarini

: Kojic acid is an organic acid that is commonly used in the pharmaceutical and cosmetic industries. This acid compound is a secondary metabolite produced by various microorganisms, one of which is Aspergillus oryzae. Typically, improving the strain can enhance kojic acid production. A mutation is one of the tools to perform strain improvement because the change in kojic acid-producing genes effectively increases kojic acid yield. Random mutagenesis is a classic approach for inducing and producing mutants with random mutations. The mutagenesis can be generated by the individual physical and chemical mutagen, combined physical and chemical mutagens, or initiate by protoplast preparation. Aspergillus strains that are exposed to physical mutagens (e.g., UV) or chemical mutagens (e.g., N-methyl-N-nitro-N-nitrosoguanidine (NTG)) showed their abilities in increasing kojic acid production. Several new mutation methods, such as Ion Beam Implantation and Atmospheric and room temperature plasma (ARTP), also showed good responses in enhancing the production of biological products such as kojic acid. This review compared different random mutagenesis methods of Aspergillus strain with various mutagen types to provide better insight for researchers in choosing the most suitable method to increase kojic acid production.


2013 ◽  
Vol 2013 ◽  
pp. 1-12 ◽  
Author(s):  
Yujin Cao ◽  
Rubing Zhang ◽  
Chao Sun ◽  
Tao Cheng ◽  
Yuhua Liu ◽  
...  

Succinate is a valuable platform chemical for multiple applications. Confronted with the exhaustion of fossil energy resources, fermentative succinate production from renewable biomass to replace the traditional petrochemical process is receiving an increasing amount of attention. During the past few years, the succinate-producing process using microbial fermentation has been made commercially available by the joint efforts of researchers in different fields. In this review, recent attempts and experiences devoted to reduce the production cost of biobased succinate are summarized, including strain improvement, fermentation engineering, and downstream processing. The key limitations and challenges faced in current microbial production systems are also proposed.


Sign in / Sign up

Export Citation Format

Share Document